The global pharmaceutical market will grow 4-6 per cent next year, exceeding $825 billion, 1 per cent more than its earlier prediction, according to IMS Health, a global drug sales tracking agency.
Its analysis predicts the global drug sales scenario over five years will augur well for generic or reverse-engineered cheap version drug makers.
Global growth will be 4-7 per cent each year through 2013. The ‘pharmerging markets,’ which include China and India, are expected to grow12-14 per cent in 2010, and 13-16 per cent over five years.
This was despite economic conditions significantly affecting some markets like Russia, Turkey, South Korea and Mexico, said the agency. The four Bric countries (Brazil, Russia, India and China), apart from Turkey, Korea and Mexico, are considered the ‘pharmerging markets,’ which has seen the highest growth recently.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
